Developer docs
API playgroundTry for free, no card

Search company profiles

Covalence Research Ltd

Full company profile

uuid00238z5

Namestring
Covalence Research Ltd
Legal namestring
Covalence Research Ltd
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Covalence Research Ltd is a privately held UK-based health economics and evidence synthesis consultancy, headquartered in Harpenden, England (company number 9358078). Founded in 2014, the firm provides specialized services to pharmaceutical and biotechnology companies developing health technologies that require evidence-based submissions to health technology assessment (HTA) bodies. Its service portfolio comprises health economic modeling and analysis (cost-utility models such as the DEVOTE and PRIME Type 2 Diabetes models), systematic literature reviews, network meta-analyses following ISPOR and NICE best-practice guidelines, medical writing and value communications, and data and dashboard development. The company reports successful submissions to NICE (UK), SMC (Scotland), Canada's Drug Agency (CDA-AMC, formerly CADTH), and AMCP (USA), with demonstrable therapy area depth across diabetes, oncology, virology, cardiovascular, autoimmune, dermatology, infectious diseases, and rare diseases.

The firm's delivery is anchored by proprietary technology assets, most notably Sourcerer — an in-house, custom-built platform for rapid systematic literature screening, operated as a sub-brand at sourcerer.pro — and the Secondary Care Medicines Data (SCMD) Dashboard, an off-the-shelf analytical product built on Shiny and Angular. Covalence also sponsors the BUGSnet Bayesian network meta-analysis project in collaboration with the University of Waterloo, stewarding open-source methodology aligned to ISPOR and NICE standards. The team of 12 professionals includes Director Richard Pollock (Cambridge, over 18 years as a health economist, 100+ peer-reviewed publications) and senior staff drawn from Oxford, Imperial College London, LSHTM, Sheffield, King's College London, and Bristol, with senior-level recruits in 2024-2026 sourced from HEOR Ltd, Lumanity (formerly BresMed), and Clarivate.

Covalence operates a professional services, sales-led go-to-market model with project-based, quote-driven engagements rather than published pricing. Distribution is direct-to-enterprise through consulting relationships with pharma and biotech clients across the UK, EU, North America, and APAC. The company is privately held with no disclosed funding rounds, no parent entity, and no public revenue. Revenue mechanics combine fee-for-service consulting with emerging productized revenue from the SCMD Dashboard and Sourcerer platform.

Short descriptiontext

Covalence Research Ltd is a UK-based health economics consultancy that delivers cost-utility modeling, systematic literature reviews, network meta-analyses, medical writing, and data dashboards to pharmaceutical and biotechnology clients preparing submissions to NICE, SMC, CDA-AMC, and AMCP.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
health economics consulting, systematic literature reviews, medical writing services, meta-analysis services, health technology assessment
Industry2 codes
PRIMARYHLAIAKAC
Value Dossier & Evidence Generation (AMCP/Global Value Dossier)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
SECONDARYHLAGAOAN
Market Access, Pricing & Reimbursement (Evidence Generation) FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Management Consulting Services8742
Product category
Health Economics and Outcomes Research (HEOR) Consulting
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Health Economics Consulting Services
TypeProfessional Services
Description

Professional consulting services including health economic modeling, cost-utility analyses, and reimbursement submissions to regulatory bodies (NICE, SMC, CADTH/CDA-AMC). Revenue generated through project-based engagements with pharmaceutical and biotech clients.

covalence-research.com
2Evidence Synthesis Services
TypeProfessional Services
Description

Systematic literature reviews, meta-analyses, and network meta-analyses conducted as professional service engagements. Forms the basis of peer-reviewed publications and reimbursement submissions.

covalence-research.com
3Medical Writing Services
TypeProfessional Services
Description

Medical writing and value communications including systematic literature reviews, global value dossiers, value messages, landscape reviews, manuscripts, posters, slide kits and medical education resources.

covalence-research.com
4Data and Dashboard Products
TypeProfessional Services
Description

Off-the-shelf offerings such as the Secondary Care Medicines Data (SCMD) Dashboard and bespoke dashboards for clients' own datasets using Shiny and Angular technologies.

covalence-research.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Sourcerer
Description

Covalence's in-house, custom-built platform for conducting systematic literature reviews.

covalence-research.com
+1 more record
Core offering1 text field

Covalence Research is a health economics and outcomes research (HEOR) consultancy that delivers health economic modelling, systematic literature reviews, meta-analyses, medical writing, and bespoke data dashboards for pharmaceutical and biotechnology clients. Their models and evidence syntheses have formed the basis of successful reimbursement submissions to NICE (UK), SMC (Scotland), CDA-AMC (Canada), and AMCP (USA). They also market the proprietary Sourcerer literature-review platform and an off-the-shelf Secondary Care Medicines Data (SCMD) Dashboard.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 100 peer-reviewed publications authored by the team
+2 more records
Product overview1 text field

Covalence Research Ltd is a health economics consultancy offering a portfolio of specialized services and proprietary tools. The core offerings include Health Economic Modeling and Analysis (featuring the DEVOTE Type 2 Diabetes cost-utility model), Systematic Literature Review (powered by their Sourcerer platform), Meta-analysis, Medical Writing, and Data and Dashboard Development. Their off-the-shelf product includes the Secondary Care Medicines Data (SCMD) Dashboard. The company sponsors the BUGSnet project for Bayesian network meta-analysis in collaboration with the University of Waterloo, and operates the Covalence Cloud platform for hosting deliverables.

Product and service1 record
1Health Economic Modeling and Analysis
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Covalence sponsors the BUGSnet project and works in close collaboration with the University of Waterloo to steward its ongoing development. BUGSnet is software for conducting network meta-analyses following best practice guidelines from ISPOR and NICE.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Johannes Pöhlmann worked on health economic evaluations including for biosimilar infliximab in Switzerland at the Zurich University of Applied Sciences.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Johannes Pöhlmann conducted research on autonomic dysfunction in heart failure at the University of Mainz (Germany).

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Neesha Nanu worked as a Research Assistant at Imperial College London on a continuously-updated systematic literature review funded by the World Cancer Research Fund International on the role of diet, nutritional status, anthropometric characteristics and physical activity in cancer prevention and prognosis.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Silvia Rabar worked for 9 years in NICE Clinical Guideline development. The company has consistently delivered models that have resulted in successful reimbursement submissions to NICE.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CRO with HEOR and market access services supporting HTA submissions. Provides end-to-end drug development services that compete for the same pharma client wallet as Covalence's specialized offering.

TypeDirect peer
Description

Dedicated HEOR research organization within RTI International, providing health economics, systematic review, and HTA submission services globally. Closely aligned to Covalence on evidence synthesis, cost-utility modeling, and value dossier production for pharma/biotech.

TypeBroad incumbent
Description

Global CRO with health economics, market access, and HTA submission capabilities. Larger and broader portfolio than Covalence but overlaps on cost-effectiveness modeling and reimbursement support for pharma clients.

TypeBroad incumbent
Description

Global biopharma services organization offering commercial, clinical, and HEOR consulting. Competes for pharma market access and evidence generation engagements at much larger scale than Covalence.

TypeBroad incumbent
Description

Global information services and consulting firm with significant real-world evidence, market access, and HEOR offerings. Overlaps Covalence on medical writing and value communications; Covalence's Martin Field joined from Clarivate.

TypeBroad incumbent
Description

Largest global CRO with a substantial HEOR and real-world evidence practice. Competes for the same pharma HEOR budget as Covalence but offers integrated clinical, commercial, and real-world evidence services at much greater scale.

TypeDirect peer
Description

Specialist in biostatistics and HEOR providing evidence generation, meta-analysis, and health economics services to pharma/biotech. Directly comparable on the evidence synthesis and statistical methodology side of Covalence's offering.

8Lumanity (formerly BresMed)
TypeDirect peer
Description

Global HEOR and market access consultancy with deep HTA submission expertise across NICE, SMC, and other agencies. Directly competes in the same value dossier, evidence generation, and health economic modeling space; Covalence's Rose Hart previously led R-modelling at Lumanity/BresMed.

TypeDirect peer
Description

UK-based health economics and outcomes research consultancy. Directly comparable as a boutique HEOR firm serving pharma/biotech clients with HTA submission support; notably, two of Covalence's recent senior hires (Tray Brown, Matt Tucker) joined from HEOR Ltd.

10Maverix Information Services
TypeDirect peer
Description

Boutique HEOR and market access consultancy serving pharma with health economic modeling, evidence synthesis, and HTA submission support. Comparable scale and service mix to Covalence, with overlap in NICE/SMC/CADTH submission work.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Covalence Research Ltd

Health Economics and Outcomes Research (HEOR) Consultingcovalence-research.com

Covalence Research Ltd is a UK-based health economics consultancy that delivers cost-utility modeling, systematic literature reviews, network meta-analyses, medical writing, and data dashboards to pharmaceutical and biotechnology clients preparing submissions to NICE, SMC, CDA-AMC, and AMCP.

What Covalence Research Ltd does

Covalence Research Ltd is a privately held UK-based health economics and evidence synthesis consultancy, headquartered in Harpenden, England (company number 9358078). Founded in 2014, the firm provides specialized services to pharmaceutical and biotechnology companies developing health technologies that require evidence-based submissions to health technology assessment (HTA) bodies. Its service portfolio comprises health economic modeling and analysis (cost-utility models such as the DEVOTE and PRIME Type 2 Diabetes models), systematic literature reviews, network meta-analyses following ISPOR and NICE best-practice guidelines, medical writing and value communications, and data and dashboard development. The company reports successful submissions to NICE (UK), SMC (Scotland), Canada's Drug Agency (CDA-AMC, formerly CADTH), and AMCP (USA), with demonstrable therapy area depth across diabetes, oncology, virology, cardiovascular, autoimmune, dermatology, infectious diseases, and rare diseases.

The firm's delivery is anchored by proprietary technology assets, most notably Sourcerer — an in-house, custom-built platform for rapid systematic literature screening, operated as a sub-brand at sourcerer.pro — and the Secondary Care Medicines Data (SCMD) Dashboard, an off-the-shelf analytical product built on Shiny and Angular. Covalence also sponsors the BUGSnet Bayesian network meta-analysis project in collaboration with the University of Waterloo, stewarding open-source methodology aligned to ISPOR and NICE standards. The team of 12 professionals includes Director Richard Pollock (Cambridge, over 18 years as a health economist, 100+ peer-reviewed publications) and senior staff drawn from Oxford, Imperial College London, LSHTM, Sheffield, King's College London, and Bristol, with senior-level recruits in 2024-2026 sourced from HEOR Ltd, Lumanity (formerly BresMed), and Clarivate.

Covalence operates a professional services, sales-led go-to-market model with project-based, quote-driven engagements rather than published pricing. Distribution is direct-to-enterprise through consulting relationships with pharma and biotech clients across the UK, EU, North America, and APAC. The company is privately held with no disclosed funding rounds, no parent entity, and no public revenue. Revenue mechanics combine fee-for-service consulting with emerging productized revenue from the SCMD Dashboard and Sourcerer platform.

Covalence Research Ltd firmographics

Firmographics
Name
Covalence Research Ltd
Legal name
Covalence Research Ltd
Website
https://covalence-research.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Covalence Research Ltd is a UK-based health economics consultancy that delivers cost-utility modeling, systematic literature reviews, network meta-analyses, medical writing, and data dashboards to pharmaceutical and biotechnology clients preparing submissions to NICE, SMC, CDA-AMC, and AMCP.
Ownership category
akta.pro rank

Covalence Research Ltd industry classification

Industry
Product category
Health Economics and Outcomes Research (HEOR) Consulting
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYHLAIAKAC
Value Dossier & Evidence Generation (AMCP/Global Value Dossier)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
SECONDARYHLAGAOAN
Market Access, Pricing & Reimbursement (Evidence Generation) FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

Keywords

  • Health economics consulting
  • Systematic literature reviews
  • Medical writing services
  • Meta-analysis services
  • Health technology assessment

Where Covalence Research Ltd is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Covalence Research Ltd business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Health Economics Consulting Services: Professional consulting services including health economic modeling, cost-utility analyses, and reimbursement submissions to regulatory bodies (NICE, SMC, CADTH/CDA-AMC). Revenue generated through project-based engagements with pharmaceutical and biotech clients.
  2. Evidence Synthesis Services: Systematic literature reviews, meta-analyses, and network meta-analyses conducted as professional service engagements. Forms the basis of peer-reviewed publications and reimbursement submissions.
  3. Medical Writing Services: Medical writing and value communications including systematic literature reviews, global value dossiers, value messages, landscape reviews, manuscripts, posters, slide kits and medical education resources.
  4. Data and Dashboard Products: Off-the-shelf offerings such as the Secondary Care Medicines Data (SCMD) Dashboard and bespoke dashboards for clients' own datasets using Shiny and Angular technologies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Covalence Research Ltd product offering

Product offering

Core offering

Covalence Research is a health economics and outcomes research (HEOR) consultancy that delivers health economic modelling, systematic literature reviews, meta-analyses, medical writing, and bespoke data dashboards for pharmaceutical and biotechnology clients. Their models and evidence syntheses have formed the basis of successful reimbursement submissions to NICE (UK), SMC (Scotland), CDA-AMC (Canada), and AMCP (USA). They also market the proprietary Sourcerer literature-review platform and an off-the-shelf Secondary Care Medicines Data (SCMD) Dashboard.

Product overview

Covalence Research Ltd is a health economics consultancy offering a portfolio of specialized services and proprietary tools. The core offerings include Health Economic Modeling and Analysis (featuring the DEVOTE Type 2 Diabetes cost-utility model), Systematic Literature Review (powered by their Sourcerer platform), Meta-analysis, Medical Writing, and Data and Dashboard Development. Their off-the-shelf product includes the Secondary Care Medicines Data (SCMD) Dashboard. The company sponsors the BUGSnet project for Bayesian network meta-analysis in collaboration with the University of Waterloo, and operates the Covalence Cloud platform for hosting deliverables.

Differentiator

Problem solved

Functional benefit

Brands

  • Sourcerer: Covalence's in-house, custom-built platform for conducting systematic literature reviews.
  • Secondary Care Medicines Data (SCMD) Dashboard

Products and services

  • Health Economic Modeling and Analysis

Quantifiable outcome

  • Over 100 peer-reviewed publications authored by the team
  • +2 more outcomes

Companies that use Covalence Research Ltd

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Covalence Research Ltd technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Covalence Research Ltd partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • University of WaterloocoreStrategic or Co-development PartnerCovalence sponsors the BUGSnet project and works in close collaboration with the University of Waterloo to steward its ongoing development. BUGSnet is software for conducting network meta-analyses following best practice guidelines from ISPOR and NICE.
  • Zurich University of Applied Sciences (Switzerland)minorStrategic or Co-development PartnerJohannes Pöhlmann worked on health economic evaluations including for biosimilar infliximab in Switzerland at the Zurich University of Applied Sciences.
  • University of Mainz (Germany)minorStrategic or Co-development PartnerJohannes Pöhlmann conducted research on autonomic dysfunction in heart failure at the University of Mainz (Germany).
  • World Cancer Research Fund InternationalminorStrategic or Co-development PartnerNeesha Nanu worked as a Research Assistant at Imperial College London on a continuously-updated systematic literature review funded by the World Cancer Research Fund International on the role of diet, nutritional status, anthropometric characteristics and physical activity in cancer prevention and prognosis.
  • NICE (National Institute for Health and Care Excellence)coreStrategic or Co-development PartnerSilvia Rabar worked for 9 years in NICE Clinical Guideline development. The company has consistently delivered models that have resulted in successful reimbursement submissions to NICE.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Covalence Research Ltd competitors and assessment

Company assessment

Broad incumbents

  • Parexel International: Global CRO with HEOR and market access services supporting HTA submissions. Provides end-to-end drug development services that compete for the same pharma client wallet as Covalence's specialized offering.
  • ICON plc: Global CRO with health economics, market access, and HTA submission capabilities. Larger and broader portfolio than Covalence but overlaps on cost-effectiveness modeling and reimbursement support for pharma clients.
  • Syneos Health: Global biopharma services organization offering commercial, clinical, and HEOR consulting. Competes for pharma market access and evidence generation engagements at much larger scale than Covalence.
  • Clarivate: Global information services and consulting firm with significant real-world evidence, market access, and HEOR offerings. Overlaps Covalence on medical writing and value communications; Covalence's Martin Field joined from Clarivate.
  • IQVIA: Largest global CRO with a substantial HEOR and real-world evidence practice. Competes for the same pharma HEOR budget as Covalence but offers integrated clinical, commercial, and real-world evidence services at much greater scale.

Direct peers

  • RTI Health Solutions: Dedicated HEOR research organization within RTI International, providing health economics, systematic review, and HTA submission services globally. Closely aligned to Covalence on evidence synthesis, cost-utility modeling, and value dossier production for pharma/biotech.
  • Cytel: Specialist in biostatistics and HEOR providing evidence generation, meta-analysis, and health economics services to pharma/biotech. Directly comparable on the evidence synthesis and statistical methodology side of Covalence's offering.
  • Lumanity (formerly BresMed): Global HEOR and market access consultancy with deep HTA submission expertise across NICE, SMC, and other agencies. Directly competes in the same value dossier, evidence generation, and health economic modeling space; Covalence's Rose Hart previously led R-modelling at Lumanity/BresMed.
  • HEOR Ltd: UK-based health economics and outcomes research consultancy. Directly comparable as a boutique HEOR firm serving pharma/biotech clients with HTA submission support; notably, two of Covalence's recent senior hires (Tray Brown, Matt Tucker) joined from HEOR Ltd.
  • Maverix Information Services: Boutique HEOR and market access consultancy serving pharma with health economic modeling, evidence synthesis, and HTA submission support. Comparable scale and service mix to Covalence, with overlap in NICE/SMC/CADTH submission work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Covalence Research Ltd social profiles

Digital presence

Covalence Research Ltd financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Covalence Research Ltd leadership team

Management profile

Number of profiles

Profiles12 records

Covalence Research Ltd funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Covalence Research Ltd M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Covalence Research Ltd

What does Covalence Research Ltd do?

Covalence Research is a health economics and outcomes research (HEOR) consultancy that delivers health economic modelling, systematic literature reviews, meta-analyses, medical writing, and bespoke data dashboards for pharmaceutical and biotechnology clients. Their models and evidence syntheses have formed the basis of successful reimbursement submissions to NICE (UK), SMC (Scotland), CDA-AMC (Canada), and AMCP (USA). They also market the proprietary Sourcerer literature-review platform and an off-the-shelf Secondary Care Medicines Data (SCMD) Dashboard.

Is Covalence Research Ltd a public or private company?

Covalence Research Ltd is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Covalence Research Ltd founded?

Covalence Research Ltd was founded in 2014. It employs 11 to 50 people.

Where is Covalence Research Ltd based?

Covalence Research Ltd is headquartered in London, United Kingdom, in the Europe region.

How does Covalence Research Ltd make money?

Four revenue lines are on record. Health Economics Consulting Services are the primary driver. The others are evidence Synthesis Services, medical Writing Services and data and Dashboard Products.

Who are Covalence Research Ltd's main competitors?

Broad incumbents on record are Parexel International, ICON plc, Syneos Health, Clarivate and IQVIA. Direct peers are RTI Health Solutions, Cytel, Lumanity (formerly BresMed), HEOR Ltd and Maverix Information Services.

Does Covalence Research Ltd have an API?

No public API is recorded for Covalence Research Ltd.

What industry is Covalence Research Ltd in?

Covalence Research Ltd's product category is Health Economics and Outcomes Research (HEOR) Consulting. Its primary akta.pro industry code is HLAIAKAC, Value Dossier & Evidence Generation (AMCP/Global Value Dossier), with a secondary code of HLAGAOAN, Market Access, Pricing & Reimbursement (Evidence Generation) FSP. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales